Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability

Hypertension

Volumn 53, Issue 2, 2009, Pages 175-181

  Phipps, Joanna A ^a   Clermont, Allen C ^a   Sinha, Sukanto ^b   Chilcote, Tamie J ^b   Bursell, Sven Erik ^c   Feener, Edward P ^a  

^a JOSLIN DIABETES CENTER   (United States)

^b ActiveSite Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF HAWAII   (United States)

Author keywords

Angiotensin II; AT 1; Diabetes; Hypertension; Kallikrein; Receptor; Retina

Indexed keywords

1 BENZYL 1H PYRAZOL 4 CARBOXYL 4 CARBAMIMIDOYLBENZYLAMIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; CANDESARTAN; CARBOXYLIC ACID DERIVATIVE; KALLIKREIN INHIBITOR; PLASMA KALLIKREIN; STREPTOZOCIN; UNCLASSIFIED DRUG; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; KALLIKREIN; KININ; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CAROTID ARTERY; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; HYPERTENSION; INJECTION; LEUKOSTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; RETINA BLOOD VESSEL; RETINAL LEUKOSTASIS; STREPTOZOCIN DIABETES; TELEMETRY; ANIMAL; BLOOD; CAPILLARY PERMEABILITY; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA ARTERY; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HYPERTENSION; KALLIKREINS; KININS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RETINAL ARTERY; STREPTOZOCIN; TETRAZOLES;

EID: 59849102068     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.117663     Document Type: Article

References (41)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91:1464-1474.
2. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic macu-lopathy. Semin Ophthalmol. 1999;14:223-232.
3. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA. 1999;96:10836-10841.
4. Girach A, Lund-Andersen H. Diabetic macular oedema: a clinical overview. Int J Clin Pract. 2007;61:88-97.
5. Roy MS, Affouf M. Six-year progression of retinopathy and associated risk factors in African American patients with type 1 diabetes mellitus: the New Jersey 725. Arch Ophthalmol. 2006;124:1297-1306.
6. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105:1801-1815.
7. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004;122:1631-1640.
8. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351:28-31.
9. Schrier RW, Estacio RO, Mehler PS, Hiatt WR. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol. 2007;3:428-438.
10. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjolie AK. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372:1394-1402.
11. Horio N, Clermont AC, Abiko A, Abiko T, Shoelson BD, Bursell SE, Feener EP. Angiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats. Diabetologia. 2004;47:113-123.
12. Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell SE, Aiello LP, Feener EP. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med. 2007;13:181-188.
13. Schmaier AH. The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1-R13.
14. Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol. 2007;120:416-422.
15. Davis AE III. The pathophysiology of hereditary angioedema. Clin Immunol. 2005;114:3-9.
16. Ebrahimian TG, Tamarat R, Clergue M, Duriez M, Levy BI, Silvestre JS. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vase Biol. 2005;25:65-70.
17. Wheeler-Schilling TH, Kohler K, Sautter M, Guenther E. Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat. Eur J Neurosci. 1999; 11:3387-3394.
18. Clermont A, Bursell SE, Feener EP. Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J HypertensSuppl. 2006;24:S73-S80.
19. Landmesser U, Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens. 2006;24(suppl):S39-S43.
20. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-935.
21. Hornig B, Kohler C, Schlink D, Tatge H, Drexler H. ATI-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism. Hypertension. 2003;41:1092-1095.
22. Yayama K, Hiyoshi H, Imazu D, Okamoto H. Angiotensin II stimulates endothelial NO synthase phosphorylation in thoracic aorta of mice with abdominal aortic banding via type 2 receptor. Hypertension. 2006;48:958-964.
23. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation. 2005;111:315-320.
24. Groger M, Lebesgue D, Pruneau D, Relton J, Kim SW, Nussberger J, Plesnila N. Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2005;25:978-989.
25. Bucci M, Roviezzo F, Posadas I, Yu J, Parente L, Sessa WC, Ignarro LJ, Cirino G. Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo. Proc Natl Acad Sci USA. 2005;102:904-908.
26. Parving HH, Larsen M, Hommel E, Lund-Andersen H. Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive type 1 (insulin-dependent) diabetic patients with background retinopathy. Diabetologia. 1989;32:440-444.
27. Gilbert RE, Kelly DJ, Cox AJ, Wilkinson-Berka JL, Rumble JR, Osicka T, Panagiotopoulos S, Lee V, Hendrich EC, Jerums G, Cooper ME. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia. 2000;43:1360-1367.
28. Kakoki M, Takahashi N, Jennette JC, Smithies O. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA. 2004;101:13302-13305.
29. Griol-Charhbili V, Messadi-Laribi E, Bascands JL, Heudes D, Meneton P, Giudicelli JF, Alhenc-Gelas F, Richer C. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J. 2005;19:1172-1174.
30. Abdouh M, Talbot S, Couture R, Hassessian HM. Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(l) and B(2) receptors. Br J Pharmacol. 2008;154:136-143.
31. Phipps J A, Feener EP. The kallikrein-kinin system in diabetic retinopathy: Lessons for the kidney. Kidney Int. 2008;73:1114-1119.
32. Funatsu H, Yamashita H, Nakanishi Y, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol. 2002;86:311-315.
33. Pelaez LI, Manriquez MC, Nath KA, Romero JC, Juncos LA. Low-dose angiotensin II enhances pressor responses without causing sustained hypertension. Hypertension. 2003;42:798-801.
34. Mukai H, Fitzgibbon WR, Ploth DW, Margolius HS. Effect of chronic bradykinin B2 receptor blockade on blood pressure of conscious Dahl salt-resistant rats. Br J Pharmacol. 1998;124:197-205.
35. Zhou W, Fu LW, Tjen ALS, Guo ZL, Longhurst JC. Role of glutamate in a visceral sympathoexcitatory reflex in rostral ventrolateral medulla of cats. Am J Physiol Heart Circ Physiol. 2006;291:H1309-H1318.
36. Zahner MR, Pan HL. Role of paraventricular nucleus in the cardiogenic sympathetic reflex in rats. Am J Physiol Regul Integr Comp Physiol. 2005;288:R420-R426.
37. Privitera PJ, Thibodeaux H, Yates P. Rostral ventrolateral medulla as a site for the central hypertensive action of kinins. Hypertension. 1994;23:52-58.
38. Hulstrom D, Svensjo E. Intravital and electron microscopic study of bradykinin-induced vascular permeability changes using FITC-dextran as a tracer. J Pathol. 1979;129:125-133.
39. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007;119:1497-1503.
40. Katsuda I, Maruyama F, Ezaki K, Sawamura T, Ichihara Y. A new type of plasma prekallikrein deficiency associated with homozygosity for Glyl04Arg and Asnl24Ser in apple domain 2 of the heavy-chain region. Eur J Haematol. 2007;79:59-68.
41. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;l 17:e510-e526.